Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to see whether ZYNRELEF revenue offsets R&D spending on next-gen oncology injectables? The answer lives in the Heron Therapeutics quarterly earnings report 10-Q filing—but combing through biotech jargon takes time. Stock Titan’s AI decodes every document the moment it hits EDGAR, giving you pipeline milestones, cash-runway metrics, and Heron Therapeutics SEC filings explained simply.
- Heron Therapeutics Form 4 insider transactions real-time – follow executive stock moves minutes after submission.
- Heron Therapeutics annual report 10-K simplified – AI highlights CINVANTI sales, royalty obligations, and trial costs.
- Heron Therapeutics 8-K material events explained – grasp FDA decisions or financings without legalese.
Need answers fast? Type questions like “How to read Heron Therapeutics’ 10-K?” or “Where is the Heron Therapeutics proxy statement executive compensation section?” —our platform serves curated links plus plain-English commentary. You’ll also find Heron Therapeutics insider trading Form 4 transactions and an at-a-glance Heron Therapeutics earnings report filing analysis so you can monitor guidance shifts tied to the biochronomer platform.
Whether you’re tracking Heron Therapeutics executive stock transactions Form 4 before earnings, comparing quarter-over-quarter R&D ratios, or simply understanding Heron Therapeutics SEC documents with AI, Stock Titan delivers real-time alerts, exportable tables, and side-by-side comparisons. Spend less time scrolling and more time acting on clear insights.
Heron Therapeutics, Inc. (HRTX) – Form 4 insider filing
EVP & Chief Development Officer William P. Forbes reported the vesting and automatic conversion of 3,874 restricted stock units (RSUs) into common shares on 07/19/2025 (transaction code “M”). No shares were sold, and the RSUs carried a $0.00 exercise price. Following the conversion, Forbes’ direct common-stock holdings increased to 138,940 shares. He still holds 38,743 unvested RSUs, which continue to vest quarterly through the original 01/19/2028 schedule. No other equity instruments or derivative transactions were disclosed.
- No cash proceeds were generated; the transaction simply moved shares from the derivative column to direct ownership.
- The filing does not indicate any open-market purchases or dispositions, suggesting the move is part of a pre-set equity-compensation plan.
Form 4 filing for Heron Therapeutics, Inc. (HRTX) discloses that Executive Vice President & Chief Financial Officer Ira Duarte converted 3,874 Restricted Stock Units (RSUs) into an equal number of common shares on 07/19/2025 (transaction code M).
Following the conversion, Duarte directly owns 152,523 HRTX common shares and retains 38,743 unvested RSUs. The RSUs originally granted on 01/19/2024 vest in 16 equal quarterly instalments; the reported tranche represents one of these scheduled releases. No shares were sold and no cash price is indicated (exercise price $0), so total insider ownership increased by the same amount as shares acquired.
No other non-derivative or derivative transactions were reported. This appears to be a routine vesting/settlement event rather than an open-market purchase or disposition.
Heron Therapeutics (HRTX) – Form 4 filing
On 19 Jul 2025, CEO & Director Craig A. Collard acquired 13,797 common shares through the vesting and settlement of an equal number of restricted stock units (RSUs) granted 19 Jan 2024. The RSUs, which carry a $0 exercise price, vest in 16 equal quarterly tranches; this filing records the fourth installment. Following the transaction Collard’s direct ownership increased to 439,749 common shares, while 137,969 RSUs remain outstanding. No shares were sold or transferred, and no option exercises or cash proceeds were reported.
The transaction is routine insider equity vesting that modestly lifts insider ownership but does not reflect a discretionary open-market purchase or sale. Market impact is expected to be minimal.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
What is the core focus of Heron Therapeutics?
How does Heron Therapeutics generate its revenue?
What differentiates Heron Therapeutics in the biotech industry?
What are the main products in Heron Therapeutics’ portfolio?
Who are the primary customers of Heron Therapeutics?
How does the biochronomer platform improve therapeutic outcomes?
What role do strategic partnerships play for Heron Therapeutics?
